HIV dementia

Current Treatment Options in Neurology

Volumn 6, Issue 2, 2004, Pages 139-151

  Nath, Avindra ^a   Berger, Joseph ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIINFLAMMATORY AGENT; CARBAMAZEPINE; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHINYLESTRADIOL; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEUROPROTECTIVE AGENT; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SELEGILINE; SILDENAFIL; STAVUDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; ATHEROSCLEROSIS; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG COST; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG POTENTIATION; DYSPNEA; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER DYSFUNCTION; MANIA; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MOUTH ULCER; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NIGHTMARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; REVIEW; SOCIOECONOMICS; VIRUS LOAD; VIRUS STRAIN; VOMITING;

EID: 4444289117     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-004-0023-6     Document Type: Review

References (79)

1. Navia BA, Jordan BD, Price RW: The AIDS dementia complex: I. Clinical features [abstract]. Ann Neurol 1986, 19: 517-524.
2. Snider WD, Simpson DM, Nielsen S, et al.: Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983, 14: 403-418.
3. Britton CB, Miller JR: Neurologic complications in acquired immunodeficiency syndrome (AIDS). Neurol Clin 1984, 2: 315-339.
4. McArthur JC, Hoover DR, Bacellar H, et al.: Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993, 43: 2245-2252.
5. Day JJ, Grant I, Atkinson JH, et al.: Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort. J Neuropsychiatry Clin Neurosci 1992, 4: 15-20.
6. Janssen ES, Wanyanwi OC, Selik RM, Stehr-Green JK: Epidemiology of human immunodeficiency encephalopathy in the United States. Neurology 1992, 42: 1472-1476.
7. Inungu JN, Mokotoff ED, Kent JB: Characteristics of HIV infection in patients fifty years or older in Michigan. AIDS Patient Care STDS 2001, 15: 567-573.
8. Wang F, So Y, Vittinghoff E, et al.: Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8: 75-82.
9. Schmitt FA, Bigley JW, McKinnis R, et al.: Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988, 319: 1573-1578.
10. Portegies P, de Gans J, Lange JM, et al.: Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989, 299: 819-821.
11. Sacktor NC, Lyles RH, Skolasky RL, et al.: Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology 1999, 52: 1640-1647.
12. Sacktor N, Lyles RH, Skolasky R, et al.: HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001, 56: 257-260.
13. Sacktor N: The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002, 8: 115-121.
14. Welch K, Morse A: The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy. AIDS Patient Care STDS 2002, 16: 75-81.
15. Price RW, Brew B, Sidtis J, et al.: The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988, 239: 586-592.
16. Selnes OA, Miller E, McArthur J, et al.: HIV-1 infection: no evidence of cognitive decline during the asymptomatic stages. The Multicenter AIDS Cohort Study. Neurology 1990, 40: 204-208.
17. Navia BA, Price RW: The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol 1987, 44: 65-69.
18. Brew BJ: AIDS dementia complex. Neurol Clin 1999, 17: 861-881.
19. Johnston JL, Miller JD, Nath A: Ocular motor dysfunction in HIV-1-infected subjects: a quantitative oculographic analysis. Neurology 1996, 46: 451-457.
20. Arendt G, Hefter H, Elsing C, et al.: Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit. J Neurol 1990, 237: 362-368.
21. Koutsilieri E, Sopper S, Scheller C, et al.: Parkinsonism in HIV dementia. J Neural Transm 2002, 109: 767-775.
22. Mirsattari SM, Power C, Nath A: Parkinsonism with HIV infection. Mov Disord 1998, 13: 684-689.
23. Norman SE, Chediak AD, Kiel M, Cohn MA: Sleep disturbances in HIV-infected homosexual men. Aids 1990, 4: 775-781.
24. Price RW, Brew BJ: The AIDS dementia complex. J Infect Dis 1988, 158: 1079-1083.
25. Mijch AM, Judd FK, Lyketsos CG, et al.: Secondary mania in patients with HIV infection: are antiretrovirals protective? J Neuropsychiatry Clin Neurosci 1999, 11: 475-480.
26. Brouillette MJ, Chouinard G, Lalonde R: Didanosine-induced mania in HIV infection. Am J Psychiatry 1994, 151: 1839-1840.
27. Modi G, Modi M, Martinus I, Vangu M: New onset seizures in HIV-infected patients without intracranial mass lesions or meningitis - a clinical, radiological and SPECT scan study. J Neurol Sci 2002, 2002: 29-34.
28. Navia BA, Jordan BD, Price RW: The AIDS dementia complex: I. Clinical features. Ann Neurol 1986, 19: 517-524.
29. Buffet R, Agut H, Chieze F, et al.: Virological markers in the cerebrospinal fluid from HIV-1-infected individuals. AIDS 1991, 5: 1419-1424.
30. Ellis RJ, Hsia K, Spector SA, et al.: Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997, 42: 679-688.
31. McArthur JC, McClernon DR, Cronin ME et al.: Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997, 42: 689-698.
32. Bouwman FH, Skolasky RL, Hes D, et al.: Variable progression of HIV-associated dementia. Neurology 1998, 50: 1814-1820.
33. Dougherty RH, Skolasky RL Jr, McArthur JC: Progression of HIV-associated dementia treated with HAART. AIDS Read 2002, 12: 69-74.
34. Nath A, Maragos WF, Avison MJ, et al.: Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol 2001, 7: 66-71.
35. Levy RM, Bredesen DE, Rosenblum ML: Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985, 62: 475-495.
36. Levy RM, Rosenbloom S, Perrett LV: Neuroradiologic findings in AIDS: a review of 200 cases. AJR Am J Roentgenol 1986, 147: 977-983.
37. Bursztyn EM, Lee BC, Bauman J: CT of acquired immunodeficiency syndrome. AJNR Am J Neuroradiol 1984, 5: 711-714.
38. Post MJ, Berger JR, Quencer RM: Asymptomatic and neurologically symptomatic HIV-seropositive individuals: prospective evaluation with cranial MR imaging. Radiology 1991, 178: 131-139.
39. Post MJ, Berger JR, Duncan R, et al.: Asymptomatic and neurologically symptomatic HIV-seropositive subjects: results of long-term MR imaging and clinical follow-up. Radiology 1993, 188: 727-733.
40. Arendt G, Hefter H, Neuen-Jacob E, et al.: Electrophysiological motor testing, MRI findings and clinical course in AIDS patients with dementia. J Neurol 1993, 240: 439-445.
41. Olsen WL, Longo FM, Mills CM, Norman D: White matter disease in AIDS: findings at MR imaging. Radiology 1988, 169: 445-448.
42. Power C, Kong PA, Crawford TO, et al.: Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 1993, 34: 339-350.
43. Berger JR, Nath A, Greenberg RN, et al.: Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 2000, 54: 921-926.
44. Paul R, Cohen R, Navia B, Tashima K: Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev 2002, 26: 353-359.
45. Thurnher MM, Schindler EG, Thurnher SA, et al.: Highly active antiretroviral therapy for patients with AIDS dementia complex: effect on MR imaging findings and clinical course. AJNR Am J Neuroradiol 2000, 21: 670-678.
46. von Giesen HJ, Antke C, Hefter H, et al.: Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings. Arch Neurol 2000, 57: 1601-1607.
47. Rottenberg DA, Sidtis JJ, Strother SC, et al.: Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996, 37: 1133-1141.
48. Hinkin CH, van Gorp WG, Mandelkern MA, et al.: Cerebral metabolic change in patients with AIDS: report of a six-month follow-up using positron-emission tomography. J Neuropsychiatry Clin Neurosci 1995, 7: 180-187.
49. Laubenberger J, Haussinger D, Bayer S, et al.: HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology 1996, 199: 805-810.
50. Avison M, Nath A, Berger J: Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? Trends Neurosci 2002, 25: 468.
51. Glass JD, Fedor H, Wesselingh SL, McArthur JC: Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995, 38: 755-762.
52. Johnson RT, Glass ID, McArthur JC, Chesebro BW: Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome. Ann Neurol 1996, 39(3): 392-395.
53. Cherner M, Masliah E, Ellis RJ, et al.: Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002, 59(10): 1563-1567.
54. Subbiah P, Mouton P, Fedor H, et al.: Stereological analysis of cerebral atrophy in human immunodeficiency virus-associated dementia. J Neuropathol Exp Neurol 1996, 55(10): 1032-1037.
55. Navia BA, Cho ES, Petito CK, Price RW: The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986, 19(6): 525-535.
56. Everall I, Luthert P, Lantos P: A review of neuronal damage in human immunodeficiency virus infection: its assessment, possible mechanism and relationship to dementia. J Neuropathol Exp Neurol 1993, 52(6): 561-566.
57. Everall I, Barnes H, Spargo E, Lantos P: Assessment of neuronal density in the putamen in human immunodeficiency virus (HIV) infection. Application of stereology and spatial analysis of quadrats. J Neurovirol 1995, 1(1): 126-129.
58. Masliah E, Ge N, Achim CL, et al.: Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 1992, 51(6): 585-593.
59. Cunningham AL, Naif H, Saksena N, et al.: HIV infection of macrophages and pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype. J Leukoc Biol 1997, 62(1): 117-125.
60. Wiley CA, Masliah E, Morey M, et al.: Neocortical damage during HIV infection. Ann Neurol 1991, 29(6): 651-657.
61. Everall IP, Heaton RK, Marcotte TD, et al.: Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 1999, 9(2): 209-217.
62. Power C, Selnes OA, Grim JA, McArthur JC: HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8(3): 273-278.
63. Price RW: Screening for the AIDS dementia complex. AIDS Read 2002, 12(1): 32-33.
64. McArthur JC, McClemon DR, Cronin MF, et al.: Relationship between human immunodeficiency virus associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997, 42: 689-698.
65. Sidtis JJ, Gatsonis C, Price RW, et al.: Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 1993, 33(4 : 343-349.
66. Arendt G, von Giesen HJ, Hefter H, Theisen A: Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection. AIDS 2001, 15(4): 493-500.
67. Altice FL, Friedland GH, Cooney EL: Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999, 13(8): 957-962.
68. Hurwitz AA, Berman JW, Lyman WD: The role of the blood-brain barrier in HIV infection of the central nervous system. Adv Neuroimmunol 1994, 4(3): 249-256.
69. Price RW, Yiannoutsos CT, Clifford DB, et al.: Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 1999, 13(13): 1677-1685.
70. Graham NM, Hoover DR, Park LP, et al.: Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. Ann Intern Med 1996, 124(12): 1031-1038.
71. Ferrando S, van Corp W, McElhiney M, et al.: Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 1998, 12(8): F65-F70.
72. von Giesen HJ, Koller H, Theisen A, Arendt G: Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J Acquir Immune Defic Syndr 2002, 29(4): 363-367.
73. Martin C, Sonnerborg A, Svensson JO, Stahle L: Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS 1999, 13: 1227-1232.
74. Haas DW, Arathoon E, Thompson MA, et al.: Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS 2000, 14: 1983-1988.
75. Consortium D: A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 1998, 50: 645-651.
76. Sacktor N, Schifitto G, McDermott MP, et al.: Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000, 54: 233-235.
77. Hriso E, Kuhn T, Masdeu JC, Grundman M: Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991, 148(11): 1558-1561.
78. Romanelli F, Jennings HR, Nath A, et al.: Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology 2000, 54: 1404-1407.
79. Mirsattari SM, Power C, Nath A: Primary headaches with HIV infection. Headache 1999, 39: 3-10.